Breast Cancer Research and Treatment

, Volume 112, Issue 2, pp 363–365 | Cite as

The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer

  • H. Clar
  • W. Renner
  • P. Krippl
  • A. Leithner
  • G. Gruber
  • T. Langsenlehner
  • G. Hofmann
  • B. Yazdani-Biuki
  • V. Clar
  • R. Windhager
  • U. Langsenlehner
Letter to the Editor

To the editor

The most common skeletal complication of breast cancer is bone metastasis, which occurs in 80% of patients with advanced disease [1, 2].

The maintenance of skeletal integrity in a healthy individual requires a balanced bone remodeling. Osteoclast-mediated bone resorption is a common factor in the pathogenesis of osteoporosis and metastatic bone disease [3, 4]. Evidence is given, that tumor mediated osteoclast activation disrupts the normal equilibrium of bone remodeling, allowing tumor cells to survive and grow in this microenvironment [4, 5].

A functional dimorphism, 13910 C/T (LCT) which is associated with adult lactose intolerance, has been suggested as a possible risk factor for osteoporosis and bone fractures, particularly in postmenopausal women [6].

In the present study, we investigated the impact of the 13910 C/T LCT polymorphism on the risk of bone metastasis in 500 breast cancer patients. Patient characteristics have been described previously [7]. The study was...


Breast Cancer Osteoporosis Bone Metastasis Lactose Intolerance Metastatic Bone Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The genotyping of LCT was financed by the Province of styria, Department of Science & Research, Transport & Technology. Special thanks to Mrs. Nicole Prutsch and Dr. Birgit Strimitzer-Riedler who heavily supported our project.


  1. 1.
    Brown JE, Neville-Webbe H, Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11(2):207–224. ReviewPubMedCrossRefGoogle Scholar
  2. 2.
    Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev Sep 5 [Epub ahead of print]Google Scholar
  3. 3.
    McClung M (2007) Role of RANKL inhibition in osteoporosis. Arthritis Res Ther 9(Suppl 1):S3PubMedCrossRefGoogle Scholar
  4. 4.
    Cicek M, Oursler MJ (2006) Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev 25(4):635–644. ReviewPubMedCrossRefGoogle Scholar
  5. 5.
    Yoneda T, Sasaki A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32(1):73–84PubMedCrossRefGoogle Scholar
  6. 6.
    Obermayer-Pietsch BM, Bonelli CM, Walter DE, Kuhn RJ, Fahrleitner-Pammer A, Berghold A, Goessler W, Stepan V, Dobnig H, Leb G, Renner W (2004) Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures. J Bone Miner Res 19(1):42–47PubMedCrossRefGoogle Scholar
  7. 7.
    Krippl P, Langsenlehner U, Renner W et al (2004) The 825C > T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer. Cancer Lett 206(1):59–62PubMedCrossRefGoogle Scholar
  8. 8.
    de Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir J (2001) Probiotics—compensation for lactase insufficiency. Am J Clin Nutr 73(2 Suppl):421–429Google Scholar
  9. 9.
    Terrio K, Auld GW (2002) Osteoporosis knowledge, calcium intake, and weight-bearing physical activity in three age groups of women. J Community Health 27(5):307–320PubMedCrossRefGoogle Scholar
  10. 10.
    Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Asil Y, Gluer CC, Schrezenmeir J (2007) Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr 137(3 Suppl 2):838–846Google Scholar
  11. 11.
    Obermayer-Pietsch BM, Gugatschka M, Reitter S, Plank W, Strele A, Walter D, Bonelli C, Goessler W, Dobnig H, Högenauer C, Renner W, Fahrleitner-Pammer A (2007) Adult-type hypolactasia and calcium availability: decreased calcium intake or impaired calcium absorption? Osteoporos Int 18(4):445–451PubMedCrossRefGoogle Scholar
  12. 12.
    Paget S (1989) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8(2):98–101PubMedGoogle Scholar
  13. 13.
    Shoback D (2007) Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 92(3):747–753. ReviewPubMedCrossRefGoogle Scholar
  14. 14.
    Roodman GD (2004) Mechanisms of bone metastasis, Review. N Engl J Med 15; 350(16):1655–1664Google Scholar
  15. 15.
    Clemons M, Dranitsaris G, Ooi W, Cole DE (2007) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 2007 May 2 [Epub ahead of print]Google Scholar
  16. 16.
    Jaschke A, Bastert G, Solomayer EF et al (2004) Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow—a longtime follow-up. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 529Google Scholar
  17. 17.
    Powles T, McCloskey E, Kurkilahti M (2004) Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 528Google Scholar
  18. 18.
    Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 527Google Scholar
  19. 19.
    Body JJ, Facon T, Coleman RE et al (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12(4):1221–1228PubMedCrossRefGoogle Scholar
  20. 20.
    McClung MR, Lewiecki EM, Cohen SB et al (2006) AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821–831Google Scholar
  21. 21.
    Clar H, Langsenlehner U, Krippl P, Renner W, Leithner A, Gruber G, Hofmann G, Yazdani-Biuki B, Langsenlehner T, Windhager R. A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients. Breast Cancer Res Treat 2007 Nov 4 [Epub ahead of print] Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2007

Authors and Affiliations

  • H. Clar
    • 1
  • W. Renner
    • 2
  • P. Krippl
    • 3
  • A. Leithner
    • 1
  • G. Gruber
    • 1
  • T. Langsenlehner
    • 4
  • G. Hofmann
    • 5
  • B. Yazdani-Biuki
    • 6
  • V. Clar
    • 7
  • R. Windhager
    • 1
  • U. Langsenlehner
    • 3
  1. 1.Department of Orthopedic SurgeryMedical University of GrazGrazAustria
  2. 2.Clinical Institute for Medical and Chemical Laboratory DiagnosisMedical University of GrazGrazAustria
  3. 3.Department of Internal Medicine, Division of OncologyGeneral Hospital FürstenfeldFurstenfeldAustria
  4. 4.Department of Therapeutic Radiology and OncologyMedical University of GrazGrazAustria
  5. 5.Department of Internal Medicine, Division of OncologyMedical University of GrazGrazAustria
  6. 6.Department of Internal Medicine, Division of RheumatologyMedical University of GrazGrazAustria
  7. 7.Department of Dentistry and Maxillofacial SurgeryMedical University of GrazGrazAustria

Personalised recommendations